Company Filing History:
1 out of 3,540 
1 out of 65 
1 out of 6 
Years Active: 2023
Title: **Pau Abrisqueta: Innovating in Cancer Research**
Introduction
Pau Abrisqueta, an accomplished inventor based in Barcelona, Spain, has made significant contributions to the field of medical research, particularly in oncology. With a focus on mantle cell lymphoma (MCL), Abrisqueta has developed innovative methods that aim to improve patient outcomes and treatment predictions.
Latest Patents
Abrisqueta holds a notable patent titled "Evaluation of mantle cell lymphoma and methods related thereto." This invention introduces methods for determining a survival predictor score for individuals diagnosed with mantle cell lymphoma. It also outlines strategies for predicting survival outcomes and selecting appropriate treatments for patients afflicted with this type of lymphoma. This patent reflects Abrisqueta's commitment to advancing cancer research and improving the quality of care for patients.
Career Highlights
Throughout his career, Pau Abrisqueta has worked with prestigious organizations, including the Department of Health and Human Services in the United States and the British Columbia Cancer Agency. His expertise in the field has allowed him to make impactful strides in cancer research, focusing on innovative approaches to treatment and patient management.
Collaborations
Abrisqueta has collaborated with notable figures in the medical research community, including esteemed researchers Louis M. Staudt and David William Scott. These collaborations have furthered his work in cancer research, enabling the development of cutting-edge methodologies aimed at enhancing the survival rates of patients with mantle cell lymphoma.
Conclusion
In summary, Pau Abrisqueta stands out as an inventor dedicated to advancing cancer treatment and research. His patent on methods related to mantle cell lymphoma signifies a promising leap forward in oncology. Through collaboration with respected professionals and work with significant institutions, Abrisqueta continues to impact the lives of many facing this challenging illness.